TargImmune Therapeutics AG is a private Swiss-based biotechnology company focused on drug development using novel targeted onco-immunotherapies. 

The Company’s principal technology is the CTPIC technology platform that utilizes a non-viral vector to target and destroy cancer cells that over-express certain receptors while simultaneously eliciting an immune response against the cancer cells.